Longeveron Positive Top-Line Results for Lomecel-B in Phase 2a Alzheimer's trial

 Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET

• Primary Endpoint of Safety Met Across all Study Groups
• Statistical Significance Met for Secondary Endpoint Composite Alzheimer’s Disease Score (CADS) for Lomecel-B™ Low-Dose and for the Pooled Lomecel-B™ Treatment Group Relative to Placebo
• Other Doses Demonstrated Numerical Slowing/Prevention of Disease Worsening Relative to Placebo
• Additional Biomarker Data Expected to be Announced in the Coming Weeks

https://www.globenewswire.com/news-release/2023/10/05/2755238/0/en/Longeveron-Announces-Positive-Top-Line-Results-for-Lomecel-B-in-its-CLEAR-MIND-Phase-2a-Clinical-Trial-in-the-Treatment-of-Mild-Alzheimer-s-Disease.html

Conference Call and Webcast Details
Investors Dial-In	1-877-407-0789
International Investors Dial-In	1-201-689-8562
Conference ID#	13741797
Call me™ Feature	Click Here
Webcast	Click Here